Baby KJ: the first person treated with CRISPR built just for him — walking and thriving at one year

Published · Researched 2026-09-22

What happened (dated facts)

KJ (Kyle Muldoon Jr.), born August 1, 2024, in Philadelphia, was diagnosed with severe neonatal-onset CPS1 deficiency — a urea-cycle disorder so rare (about one in a million) it is fatal for roughly half of affected infants; the only long-term treatment was a liver transplant. Physicians at Children's Hospital of Philadelphia and Penn Medicine (Drs. Rebecca Ahrens-Nicklas and Kiran Musunuru) designed a personalized CRISPR base editor for KJ's exact mutation in about six months; after FDA clearance, he received three infusions (February–April 2025) and his case was published in the New England Journal of Medicine in May 2025. On February 25, 2026, CHOP marked the one-year anniversary: KJ is walking and talking, has had no serious side effects, tolerates more dietary protein, needs less nitrogen-scavenging medication, and shows better ammonia control during childhood illnesses. He was named to Nature's 10 people who shaped science in 2025 ("trailblazing baby"); his doctors were named to the TIME 100 in April 2026; and in July 2026 ARPA-H awarded $160 million to seven teams (THRIVE) to turn this one-off achievement into a repeatable platform for rare pediatric diseases.

Why it is genuinely positive

A baby who would likely have died or needed a liver transplant is instead walking, talking, and eating more normally — because scientists built a medicine for exactly one person, in six months, and it worked. It is the first proof that ultra-rare genetic diseases can be treated with bespoke gene editing, and the $160M federal program now exists precisely to scale what KJ's case proved possible.

Social pulse

Circulating on Threads: biomeetsai (Aug 21, 2026) — "KJ Muldoon — first person ever treated with a gene therapy built for his personal mutation. He's walking now." A 2026 YouTube documentary ("The First CRISPR Patient Went Home") traces the story for a general audience. Press coverage spans CBS News, STAT/Boston Globe, and the ARPA-H announcement. The tone across sources is wonder at the precedent, with honest notes that it is not yet scalable.

Verified quotes

• "It's amazing to see KJ hit these milestones. While this treatment isn't a cure, after three infusions from February through April 2025, KJ has tolerated it well with no serious side effects. He's able to handle more dietary protein, requires less nitrogen-scavenging medication, and we're seeing better control of ammonia levels during colds and similar childhood illnesses. He will continue to be monitored closely to track long-term outcomes." — Dr. Rebecca Ahrens-Nicklas, director of CHOP's Gene Therapy for Inherited Metabolic Disorders Frontier Program (CHOP press release via PR Newswire, Feb 25, 2026).

Verification

• Tier: 2
• Primary source: Children's Hospital of Philadelphia press release (Feb 25, 2026, one-year anniversary) + NEJM publication (May 2025). Proves: first personalized CRISPR therapy, three infusions, walking/talking at one year, no serious side effects, improved metabolic control.
• Social sources: Threads — biomeetsai (Aug 21, 2026, "He's walking now"); YouTube documentary (2026) + STAT/Boston Globe coverage of the ARPA-H THRIVE program. Proves: sustained public circulation of the milestone into 2026.
• Positivity check: a real child, alive and thriving because of a bespoke treatment — with the non-cure caveat and scalability limits stated in CHOP's own words. Passed.

Key facts

UNVERIFIED points

• Long-term durability is unknown; KJ will be monitored for life.
• Treatment cost was not disclosed (STAT: "No one has said how much it cost").
• No CHOP-released photos of KJ were returned by image search this session; do not present generic baby photos as KJ.